Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948931 | 1.00 | MAPT (0.63) | MAPTMEN1KMT2ANT5EMAPK1 | |
| SCHEMBL10720749 | 0.86 | MAPT (0.63) | MAPTMEN1KMT2AMAPK1GUSB | |
| SCHEMBL10628268 | 0.84 | NT5E (0.52) | MAPTMEN1KMT2ANT5EMAPK1 | |
| SCHEMBL16147671 | 0.84 | NT5E (0.61) | MAPTMEN1KMT2ANT5EMAPK1 | |
| SCHEMBL108329 | 0.84 | NT5E (0.61) | MAPTMEN1KMT2ANT5EMAPK1 | |
| SCHEMBL141078 | 0.83 | NT5E (0.60) | MAPTMEN1KMT2ANT5EMAPK1 | |
| SCHEMBL141080 | 0.83 | NT5E (0.60) | MAPTMEN1KMT2ANT5EMAPK1 | |
| SCHEMBL141081 | 0.83 | NT5E (0.60) | MAPTMEN1KMT2ANT5EMAPK1 | |
| SCHEMBL31715811 | 0.81 | MAPT (0.73) | MAPTMEN1KMT2AMAPK1GFER | |
| SCHEMBL9225420 | 0.80 | NT5E (0.67) | MAPTMEN1KMT2ANT5EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1895841-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | Brigham Young University (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | MANOHARAN MUTHIAH | 2007-05-31 | — | — | US | disclosed |
| EP-1743901-A2 | Oligonucleotides having A-DNA or B-DNA form | ISIS PHARMACEUTICALS, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006138396-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | BRIGHAM YOUNG UNIVERSITY, TRANSFER TECHNOLOGY OFFICE (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7119184-B2 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1100809-B1 | RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED | ISIS PHARMACEUTICALS INC (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6737520-B2 | FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20040009938-A1 | Methods of enhancing renal uptake of oligonucleotides | ISIS PHARMACEUTICAL INC. | 2004-01-15 | — | — | US | disclosed |
| US-6673912-B1 | 2′-O-aminoethyloxyethyl-modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-6653458-B1 | Phosphodiester or phosphorothioate internucleotide linkages at 2',5' positions; substituents at 3'; nuclease resistance and increased binding affinity; use as antisense agents | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| EP-1180113-A4 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6369209-B1 | AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1180113-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-20 | — | — | EP | disclosed |
| US-6271358-B1 | FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| EP-1102787-A1 | 2'-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000066609-A1 | OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6043352-A | INCREASED HYBRIDIZATION BINDING AFFINITY AND NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| WO-2000008044-A1 | 2'-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | MAPT 4326/4885MEN1 2146/4885KMT2A 3376/4885 |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | MAPT 4326/4885MEN1 2146/4885KMT2A 3376/4885 |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | RNASEH1, RNGTT, ADAR | MAPT 4375/4885MEN1 2294/4885KMT2A 2796/4885 |
| US-20040009938-A1 | Methods of enhancing renal uptake of oligonucleotides | NUDT1, SLC29A2, DUT | MAPT 4522/4885MEN1 2516/4885KMT2A 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.